AUSTIN, Texas — Patients on dialysis who are hyporesponsive to anemia treatment will likely experience more red blood cell transfusions, according to data presented at the National Kidney Foundation Spring Clinical Meetings.“Hyporesponse (hypoR) to erythropoiesis-stimulating agents (ESAs) is associated with adverse events and poor outcomes leading to high health care